Register and join to learn about a new T-cell receptor (TCR) that targets CD22, being developed by the National Cancer Institute (NCI) as a cellular immunotherapy for the treatment of lymphomas and leukemias. CD22 TCR-T cells cleared leukemia at clinically relevant doses without causing systemic cytokine elevation.
This webinar will discuss (i) novel CD22 specific TCR-T cells that reduce tumor burden at clinically relevant doses (ii) a new therapeutic method using the novel CD22 specific TCR-T cells that overcomes current treatment limitations for hematologic malignancies. The webinar will be presented by Dr. Kazusa Ishii (Physician-Scientist Early Investigator, Head of Hematologic Malignancies Cellular Therapy Group, National Cancer Institute, NIH). This technology is available for licensing and collaborative development engagement.